Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.58 ^USD	+2.60%		-4.24%	+3.27%

Apr. 22	Transcript : Lexicon Pharmaceuticals, Inc. - Analyst/Investor Day
Mar. 25	Lexicon Pharmaceuticals Files Prospectus for Secondary Offering	MT

Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 11, 2024 at 07:15 am EDT

Lexicon Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 0.702 million compared to USD 0.028 million a year ago. Net loss was USD 48.24 million compared to USD 30.49 million a year ago.

Basic loss per share from continuing operations was USD 0.2 compared to USD 0.16 a year ago.

Latest news about Lexicon Pharmaceuticals, Inc.

Transcript : Lexicon Pharmaceuticals, Inc. - Analyst/Investor Day	Apr. 22
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering	Mar. 25	MT
Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients	Mar. 12	MT
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease	Mar. 12	CI
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup	Mar. 11	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	Mar. 11	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	Mar. 11	MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Jump	Mar. 11	MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Gain Pre-Bell	Mar. 11	MT
Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin	Mar. 11	DJ
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Reports Q4 Revenue $702,000	Mar. 11	MT
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11	CI
Lexicon Pharmaceuticals, Inc Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA	Mar. 11	CI
Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding	Mar. 10	CI
Transcript : Lexicon Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM	Jan. 11
Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference	Jan. 08	CI
Lexicon Pharmaceuticals, Inc. and Lexicon Pharmaceuticals (New Jersey), Inc Enter into Fourth Amendment to its Loan and Security Agreement with Oxford Finance LLC	Dec. 29	CI
Lexicon Enrolls First Patient in Phase 2b Trial of Potential Non-Opioid Drug for Diabetic Neuropathic Pain	Nov. 30	MT
Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain	Nov. 30	CI
Lexicon Says Phase 3 Data of Sotagliflozin Show Risk Reductions in Heart Failure, Major Adverse Cardiovascular Events	Nov. 13	MT
Lexicon Pharmaceuticals, Inc. Announces Post Hoc Analysis of Clinical Data from the SCORED Trial	Nov. 12	CI
Transcript : Lexicon Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Reports Q3 Revenue $162,000	Nov. 08	MT

Chart Lexicon Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Lexicon Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.58 USD

Average target price

5.333 USD

Spread / Average Target

+237.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LEXICON PHARMACEUTICALS, INC.	+3.27%	389M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs